Key Drivers
- Robust Liquidity
- Margin Compression
- Strong Cashflow
AIAI Summary
VCEL has evolved into a cash-generative commercial biologics company, but at ~55x EBITDA its upside now depends on MACI sustaining strong adoption while margins recover; investors should favor evidence of operating leverage and treat any growth deceleration or continued margin compression as a valuation-reset risk.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Robust Liquidity
- •Margin Compression
- •Strong Cashflow
VCEL offers strong liquidity and cash flow, but margin pressure, negative retained earnings, high stock compensation, and an expensive valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Short-term downtrend
- •Support holding
- •Resistance overhead
VCEL remains in a short-term downtrend over the last month, but holding above $39.60 and reclaiming $40.90 could support further recovery.
Rebounded roughly 5.7% from the $37.87 low
Sentiment & News
Key News Insights:
- •Institutional buying
- •MACI expansion
- •Capacity readiness
Vericel's new institutional backing and MACI growth catalysts strengthen its outlook, though UK and ankle expansions remain pending.
The developments are modestly positive for Vericel, supporting growth expectations while execution on pipeline expansions remains key
Similar Companies in Healthcare
Other companies in the same sector with AI ratings